IRIDEX, QUANTEL in Global Licensing Agreement

IRIDEX Corporation (NASDAQ: IRIX) today announced that IRIDEX and QUANTEL Medical have signed a global patent licensing agreement that gives QUANTEL access to IRIDEX' MicroPulse technology.  Our proprietary technology provides ophthalmologists a noninvasive treatment for sight-threatening diseases of the eye, including complications associated with diabetes.   Unlike conventional laser therapy, MicroPulse spares the eye tissue responsible for vision while producing comparable clinical effect to traditional methods that destroy tissue. "There is a significant need in the market place for efficient and durable therapies for retinal diseases associated with the growth of diabetes and the aging population," stated Will Moore, IRIDEX President and CEO.  He continued, "With 10-year follow up data, a growing global user base, and significant patent protection, MicroPulse is emerging as a future standard of care." The license agreement will allow QUANTEL to market and display IRIDEX' MicroPulse technology for their range of high quality clinical lasers and is the next step in gaining broad market availability of MicroPulse photocoagulation lasers. Both QUANTEL and IRIDEX offer a full line of laser systems that offer standard photocoagulation See full press release